
BioPharma Dive
1,495 FOLLOWERS
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
BioPharma Dive
3d ago
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff ..read more
BioPharma Dive
3d ago
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the new company with a bigger cash balance and three drugs in testing ..read more
BioPharma Dive
3d ago
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations ..read more
BioPharma Dive
3d ago
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call.  ..read more
BioPharma Dive
4d ago
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January ..read more
BioPharma Dive
4d ago
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and is around 1,000 prescriptions weekly by late January ..read more
BioPharma Dive
4d ago
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead.  ..read more
BioPharma Dive
4d ago
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use ..read more
BioPharma Dive
4d ago
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer duration in the new trial ..read more
BioPharma Dive
4d ago
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million ..read more